DKSH has been appointed by Hasten Biopharmaceutical Co., Ltd., a China-based innovative biopharmaceutical company with focus on chronic diseases and critical care areas, to support its "Pan-Asian" growth ambitions. The collaboration, which starts in Thailand, gives more patients in this market access to high-quality medication for chronic diseases such as hypertension and diabetes.
Bangkok, Thailand, August 26, 2024 - DKSH Business Unit Healthcare, a Strategic Healthcare Solutions Partner and leading provider of Market Expansion Services for pharmaceutical, over-the-counter (OTC), consumer health and medical device companies, has signed an exclusive agreement with HP Bidco 2 Limited, an affiliate of Hasten Biopharmaceutical Co., Ltd. for Thailand. Under the agreement, DKSH will improve the availability and accessibility of Hasten's products across hospitals, clinics and pharmacies in Thailand through distribution, logistics, marketing and sales services.
Hasten is on a growth mission to help more patients get access to medicines for chronic diseases, such as hypertension and diabetes, and critical care areas. The company recently acquired asset rights, and will also own the Marketing Authorization Holder (MAH) rights for 14 Celltrion legacy products in eight markets, including Thailand, one of the largest markets in Asia.
According to the National Health Examination Survey, in 2021, an estimated 14 million Thais suffered from hypertension[1]. The Department of Disease Control states that approximately 300,000 new diabetes patients were diagnosed in Thailand in 2022, twice as many as in 2021. This signals an increased need for easy access to high-quality medication in these critical areas.
Hanson Zheng, Senior Vice President, Head of Commercial Excellence, Hasten Biopharmaceutical Co., Ltd. said: "Together with DKSH, we will improve patients' accessibility and health outcomes to advanced healthcare solutions and provide support to doctors across Thailand. Moreover, working with DKSH allows us to focus on introducing innovative products and optimize our product portfolio, while enhancing our research and production capabilities. DKSH's expertise, efficiency and proven track record in helping companies grow gives Hasten confidence in the long-term cooperation."
Patrik Grande, Vice President, Business Unit Healthcare, DKSH Thailand, said: "Hasten is a well-established biopharma company with strong growth potential. Selecting DKSH as their growth partner is testament to our expertise in building brands and understanding of specialized therapeutic areas. DKSH has a strong platform of integrated solutions specialized in key disease areas around cardio-metabolic and renal, oncology and immunology, neuroscience-pain, dermatology, and OTC. With our network, insights and capabilities in commercial excellence, medico-marketing, patient solutions and digital engagement, our aim is to improve the lives of Thai patients, ensuring more eligible patients benefit from Hasten medicines."
"At DKSH Thailand, we pride ourselves on being a truly end-to-end strategic partner of choice, connecting the entire healthcare ecosystem to achieve better healthcare for all and enrich people's lives. This partnership with Hasten reinforces our commitment to these values and our vision of delivering superior healthcare outcomes," he added.
[1] World Health Organization (2023): Thailand: Improving hypertension care cascade with more than 60% control rate through innovation. https://www.who.int/southeastasia/news/detail/31-05-2023-thailand-improving-hypertension-care-cascade-with-more-than-60-control-rate-through-innovation